Selectivity of pharmacological tools: Implications for use in cell physiology. A Review in the Theme: Cell Signaling: Proteins, Pathways and Mechanisms

American Journal of Physiology - Cell Physiology

Volumn 308, Issue 7, 2015, Pages C505-C520

  Michel, Martin C ^a   Seifert, Roland ^b  

^a JOHANNES GUTENBERG UNIVERSITY   (Germany)

^b HANNOVER MEDICAL SCHOOL   (Germany)

Author keywords

122; 230A; 536; Amiloride; Amiodarone; Biased signaling; Competitive antagonism; Functional antagonism; Inverse agonism; Selectivity; SQ22; SR 59; Suramin; U 73

Indexed keywords

9 (TETRAHYDRO 2 FURYL)ADENINE; AGENTS INTERACTING WITH TRANSMITTER, HORMONE OR DRUG RECEPTORS; ALPHA 1 ADRENERGIC RECEPTOR; ANGIOTENSIN 1 RECEPTOR; ANGIOTENSIN RECEPTOR; BETA 2 ADRENERGIC RECEPTOR; BETA 3 ADRENERGIC RECEPTOR; BETA ARRESTIN 1; CHLOROETHYLCLONIDINE; CYCLIC AMP; DARIFENACIN; FORMYLPEPTIDE RECEPTOR; G PROTEIN COUPLED RECEPTOR; GUANINE NUCLEOTIDE BINDING PROTEIN; HISTAMINE RECEPTOR; LOSARTAN; MEPYRAMINE; METHYLSCOPOLAMINE; MUSCARINIC AGENT; MUSCARINIC RECEPTOR; OXYBUTYNIN; RECEPTOR BLOCKING AGENT; RECEPTOR RESERVE; SCOPOLAMINE; SOLIFENACIN; TOLTERODINE; TROSPIUM CHLORIDE; UNINDEXED DRUG; VALSARTAN; VASOPRESSIN RECEPTOR; 5 [2 [[2 HYDROXY 3 [4 (1 METHYL 4 TRIFLUOROMETHYL 2 IMIDAZOLYL)PHENOXY]PROPYL]AMINO]ETHOXY]SALICYLAMIDE; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; BETA ADRENERGIC RECEPTOR STIMULATING AGENT; IMIDAZOLE DERIVATIVE; PROTEIN BINDING;

AMINO ACID SEQUENCE; ANALYTIC METHOD; ARTICLE; BINDING AFFINITY; BINDING SITE; BLOOD BRAIN BARRIER; CELL FREE SYSTEM; CELL FUNCTION; CELL MEMBRANE PERMEABILITY; COMPETITIVE INHIBITION; CONCENTRATION RESPONSE; DRUG BRAIN LEVEL; DRUG POTENCY; DRUG RECEPTOR BINDING; DRUG SELECTIVITY; HUMAN; INHIBITION CONSTANT; INTRACELLULAR SIGNALING; INVERSE AGONISM; LIGAND BINDING; LIPOPHILICITY; NONHUMAN; PRIORITY JOURNAL; RADIOASSAY; RECEPTOR AFFINITY; RECEPTOR DENSITY; RECEPTOR DOWN REGULATION; RECEPTOR UPREGULATION; SIMULATION; SPECIES DIFFERENCE; AGONISTS; ANIMAL; ANTAGONISTS AND INHIBITORS; CELL COMMUNICATION; DRUG EFFECTS; METABOLISM; PHYSIOLOGY; SIGNAL TRANSDUCTION;

ADRENERGIC BETA-AGONISTS; ADRENERGIC BETA-ANTAGONISTS; ANIMALS; CELL COMMUNICATION; CELL PHYSIOLOGICAL PHENOMENA; HUMANS; IMIDAZOLES; PROTEIN BINDING; RECEPTORS, G-PROTEIN-COUPLED; SIGNAL TRANSDUCTION;

EID: 84926391921     PISSN: 03636143     EISSN: 15221563     Source Type: Journal    
DOI: 10.1152/ajpcell.00389.2014     Document Type: Article

References (208)

1. Abbracchio MP, Burnstock G, Boeynaems JM, Barnard EA, Boyer JL, Kennedy C, Knight GE, Fumagalli M, Gachet C, Jacobson KA, Weisman GA. International Union of Pharmacology LVIII: update on the P2Y G protein-coupled nucleotide receptors: from molecular mechanisms and pathophysiology to therapy. Pharmacol Rev 58: 281-341, 2006.
2. Adams MN, Pagel CN, Mackie EJ, Hooper JD. Evaluation of antibodies directed against human protease-activated receptor-2. Naunyn Schmiedebergs Arch Pharmacol 385: 861-873, 2012.
3. Aiglstorfer I, Uffrecht A, Gessele K, Moser C, Schuster A, Merz S, Malawska B, Bernhardt G, Dove S, Buschauer A. NPY Y1 antagonists: structure-activity relationship of arginine derivatives and hybrid compounds with arpromidine-like partial structures. Regul Pept 75/76: 9-21, 1998.
4. Allen JA, Yost JM, Setola V, Chen X, Sassano MF, Chen M, Peterson S, Yadav PN, Huang XP, Feng B, Jensen NH, Che X, Bai X, Frye SV, Wetsel WC, Caron MG, Javitch JA, Roth BL, Jin J. Discovery of β-arrestin-biased dopamine D2 ligands for probing signal transduction pathways essential for antipsychotic efficacy. Proc Natl Acad Sci USA 108: 18488-18493, 2011.
5. Anand-Srivastava MB. Amiloride interacts with guanine nucleotide regulatory proteins and attenuates the hormonal inhibition of adenylate cyclase. J Biol Chem 264: 9491-9496, 1989.
6. Ancellin N, Hla T. Differential pharmacological properties and signal transduction of the sphingosine 1-phosphate receptors EDG-1, EDG-3, and EDG-5. J Biol Chem 274: 18997-19002, 1999.
7. Appl H, Holzammer T, Dove S, Haen E, Straßer A, Seifert R. Interactions of recombinant human histamine H1, H2, H3, and H4 receptors with 34 antidepressants and antipsychotics. Naunyn Schmiedebergs Arch Pharmacol 385: 145-170, 2012.
8. Arunlakshana O, Schild HO. Some quantitative uses of drug antagonists. Br J Pharmacol 14: 48-58, 1959.
9. Ashton JC, Zheng Y, Darlington C, Baek JH, Smith PF. Cannabinoid CB2 receptor immunolabelling in the healthy brain—still a liver possibility. Naunyn Schmiedebergs Arch Pharmacol 387: 301, 2014.
10. Baell J, Walters MA. Chemical con artists foil drug discovery. Nature 513: 481-483, 2014.
11. Bain J, McLauchlan H, Elliott M, Cohen P. The specificities of protein kinase inhibitors: an update. Biochem J 371: 199-204, 2003.
12. Baker JG. A study of antagonist affinities for the human histamine H2 receptor. Br J Pharmacol 153: 1011-1021, 2008.
13. Barann M, Stamer UM, Lyutenska M, Stüber F, Bönisch H, Urban B. Effects of opioids on human serotonin transporters. Naunyn Schmiedebergs Arch Pharmacol 388: 43-49, 2015.
14. Beermann S, Seifert R, Neumann D. Commercially available antibodies against human and murine histamine H4-receptor lack specificity. Naunyn Schmiedebergs Arch Pharmacol 385: 125-135, 2012.
15. Beindl W, Mitterauer T, Hohenegger M, Ijzerman AP, Nanoff C, Freissmuth M. Inhibition of receptor/G protein coupling by suramin analogues. Mol Pharmacol 50: 415-423, 1996.
16. Benes J, Varejkova E, Farar V, Novakova M, Myslivecek J. Decrease in heart adrenoceptor gene expression and receptor number as compensatory tool for preserved heart function and biological rhythm in M2 KO animals. Naunyn Schmiedebergs Arch Pharmacol 385: 1161-1173, 2012.
17. Bitterman JL, Ramos-Esperitu L, Diaz A, Levin LR, Buck J. Pharmacological distinction between soluble and transmembrane adenylyl cyclases. J Pharmacol Exp Ther 347: 589-598, 2013.
18. Böhmer T, Pfeiffer N, Gericke A. Three commerical antibodies against α1-adrenergic receptor subtypes lack specificity in paraffin-embedded sections of murine tissues. Naunyn Schmiedebergs Arch Pharmacol 387: 703-706, 2014.
19. Brahmadevara N, Shaw AM, MacDonald A.α1-Adrenoceptor antagonist properties of CGP 12177A and other β-adrenoceptor ligands: evidence against β3-or atypical β-adrenoceptors in rat aorta. Br J Pharmacol 142: 781-787, 2004.
20. Brand CS, Hocker HJ, Gorfe AA, Cavasotto CN, Dessauer CW. Isoform selectivity of adenylyl cyclase inhibitors: characterization of known and novel compounds. J Pharmacol Exp Ther 347: 265-275, 2013.
21. Braun K, Rettinger J, Ganso M, Kassack M, Hildebrandt C, Ullmann H, Nickel P, Schmalzing G, Lambrecht G. NF449: a subnanomolar potency antagonist at recombinant rat P2X1 receptors. Naunyn Schmiedebergs Arch Pharmacol 364: 285-290, 2001.
22. Brodde OE.β-Adrenoceptor blocker treatment and the cardiac β -adrenoceptor-G-protein(s)-adenylyl cyclase system in chronic heart failure. Naunyn Schmiedebergs Arch Pharmacol 374: 361-372, 2007.
23. Brodde OE, Michel MC. Adrenergic and muscarinic receptors in the human heart. Pharmacol Rev 51: 651-689, 1999.
24. Brown L, Deighton NM, Bals S, Söhlmann W, Zerkowski HR, Michel MC, Brodde OE. Spare receptors for β-adrenoceptor-mediated positive inotropic effects of catecholamines in the human heart. J Cardiovasc Pharmacol 19: 222-232, 1992.
25. Brunskole Hummel I, Reinartz MT, Kölble S, Burhenne H, Schwede F, Buschauer A, Seifert R. Dissociations in the effects of β2-adrenergic receptor agonists on cAMP formation and superoxide production in human neutrophils: support for the concept of functional selectivity. PLoS One 8: e64556, 2013.
26. Burde R, Dippel E, Seifert R. Receptor-independent G protein activation may account for the stimulatory effects of first-generation H1-receptor antagonists in HL-60 cells, basophils, and mast cells. Biochem Pharmacol 51: 125-131, 1996.
27. Bylund DB, Eikenberg DC, Hieble JP, Langer SZ, Lefkowitz RJ, Minneman KP, Molinoff PB, Ruffolo RR Jr, Trendelenburg U. International Union of Pharmacology nomenclature of adrenoceptors. Pharmacol Rev 46: 121-136, 1994.
28. Callegari E, Malhotra B, Bungay PJ, Webster R, Fenner KS, Kempshhall S, LaPerle JL, Michel MC, Kay GG. A comprehensive nonclinical evaluation of the CNS penetration potential of antimuscarinic agents for the treatment of overactive bladder. Br J Clin Pharmacol 72: 235-246, 2011.
29. Candelore MR, Deng L, Tota L, Guan XM, Amend A, Liu Y, Newbold R, Cascieri MA, Weber AE. Potent and selective human β3-adrenergic receptor antagonists. J Pharmacol Exp Ther 290: 649-655, 1999.
30. Caulfield MP, Birdsall NJ. International Union of Pharmacology. XVII. Classification of muscarinic acetylcholine receptors. Pharmacol Rev 50: 279-290, 1998.
31. Cecyre B, Thomas S, Ptito M, Casanova C, Bouchard JF. Evaluation of the specificity of antibodies raised against cannabinoid receptor type 2 in the mouse retina. Naunyn Schmiedebergs Arch Pharmacol 387: 175-184, 2014.
32. Cernecka H, Ochodnicky P, Lamers WH, Michel MC. Specificity evaluation of antibodies against human β3-adrenoceptors. Naunyn Schmiedebergs Arch Pharmacol 385: 875-882, 2012.
33. Cernecka H, Pradidarcheep W, Lamers WH, Schmidt M, Michel MC. Rat β3-adrenoceptor protein expression: antibody validation and distribution in rat gastrointestinal and urogenital tissues. Naunyn Schmiedebergs Arch Pharmacol 387: 1117-1127, 2014.
34. Cernecka H, Sand C, Michel MC. The odd sibling: features of β3-adrenoceptor pharmacology. Mol Pharmacol 86: 479-484, 2014.
35. Chen X, Sassano MF, Zheng L, Setola V, Chen M, Bai X, Frye SV, Wetsel WC, Roth BL, Jin J. Structure-functional selectivity relationship studies of β-arrestin-biased dopamine D2 receptor agonists. J Med Chem 55: 7141-7153, 2012.
36. Chen Z, Zhang X, Ying L, Dou D, Liu Y, Liu L, Feng H, Yu X, Leung SW, Vanhoutte PM, Gao Y. cIMP synthesized by sGC as a mediator of hypoxic contraction of coronary artery. Am J Physiol Heart Circ Physiol 307: H328-H336, 2014.
37. Cheng YC, Prusoff WH. Relationship between the inhibition constant (Ki) and the concentration of inhibitor which causes 50 per cent inhibition (I50) of an enzymatic reaction. Biochem Pharmacol 22: 3099-3108, 1973.
38. Chi Y, Gao K, Zhang H, Takeda M, Yao J. Suppression of cell membrane permeability by suramin: involvement of its inhibitory actions on connexin 43 hemichannels. Br J Pharmacol 171: 3448-3462, 2014.
39. Chidiac P, Hebert TE, Valiquette M, Dennis M, Bouvier M. Inverse agonist activity of β-adrenergic antagonists. Mol Pharmacol 45: 490-499, 1994.
40. Chidlow G, Melena J, Osborne NN. Betaxolol, a β1-adrenoceptor antagonist, reduces Na+ influx into cortical synaptosomes by direct interaction with Na+ channels: comparison with other β-adrenoceptor antagonists. Br J Pharmacol 130: 759-766, 2000.
41. Cho H, Youm JB, Ryu SY, Earm YE, Ho WK. Inhibition of acetylcholine-activated K+ currents by U73122 is mediated by the inhibition of PIP2-channel interaction. Br J Pharmacol 134: 1066-1072, 2001.
42. Christopoulos A, Changeux JP, Catterall WA, Fabbro D, Burris TP, Cidlowski JA, Olsen RW, Peters JA, Neubig RR, Pin JP, Sexton PM, Kenakin TP, Ehlert FJ, Spedding M, Langmead CJ. International Union of Basic and Clinical Pharmacology. XC. Multisite pharmacology: recommendations for the nomenclature of receptor allosterisms and allosteric ligands. Pharmacol Rev 66: 918-947, 2014.
43. Clark JD, Limbird LE. Na+-H+ exchanger subtypes: a predictive review. Am J Physiol Cell Physiol 261: C945-C953, 1991.
44. Conley JM, Brand CS, Bogard AS, Pratt EP, Xu R, Hockerman GH, Ostrom RS, Dessauer CW, Watts VJ. Development of a high-throughput screening paradigm for the discovery of small-molecule modulators of adenylyl cyclase: identification of an adenylyl cyclase 2 inhibitor. J Pharmacol Exp Ther 347: 276-287, 2013.
45. Cotecchia S. Constitutive activity and inverse agonism at the α1 adrenoceptors. Biochem Pharmacol 73: 1076-1083, 2007.
46. Daaka Y, Luttrell LM, Lefkowitz RJ. Switching of the coupling of the β2-adrenergic receptor to different G proteins by protein kinase A. Nature 390: 88-91, 1997.
47. Davies SP, Reddy H, Caivano M, Cohen P. Specificity and mechanism of action of some commonly used protein kinase inhibitors. Biochem J 351: 95-105, 2000.
48. Davis MI, Hunt JP, Herrgard S, Ciceri P, Wodicka LM, Pallares G, Hocker M, Treiber DK, Zarrinkar PP. Comprehensive analysis of kinase inhibitor selectivity. Nat Biotechnol 29: 1046-1051, 2011.
49. de Gasparo M, Whitebread S. Binding of valsartan to mammalian angiotensin AT1 receptors. Regul Pept 59: 303-311, 1995.
50. De Lean A. Amiloride potentiates atrial natriuretic factor inhibitory action by increasing receptor binding in bovine adrenal zona glomerulosa. Life Sci 39: 1109-1116, 1986.
51. DeWire SM, Yamashita DS, Rominger DH, Liu G, Cowan CL, Graczyk TM, Chen XT, Pitis PM, Gotchev D, Yuan C, Koblish M, Lark MW, Violin JD. A G protein-biased ligand at the μ-opioid receptor is potently analgesic with reduced gastrointestinal and respiratory dysfunction compared with morphine. J Pharmacol Exp Ther 344: 708-717, 2013.
52. Diamant S, Eldar-Geva T, Atlas D. Imidazoline binding sites in human placenta: evidence for heterogeneity and a search for physiological function. Br J Pharmacol 106: 101-108, 1992.
53. El-Kholy W, MacDonald PE, Lin JH, Wang J, Fox JM, Light PE, Wang Q, Tsushima RG, Wheeler MB. The phosphatidylinositol 3-kinase inhibitor LY294002 potently blocks Kv currents via a direct mechanism. FASEB J 17: 720-722, 2003.
54. Eltze M, Mutschler E, Lambrecht G. Affinity profiles of pizotifen, ketotifen and other tricyclic antimuscarinics at muscarinic receptor subtypes M1, M2 and M3. Eur J Pharmacol 211: 283-293, 1992.
55. Emery AC, Eiden MV, Eiden LE. A new site and mechanism of action for the widely used adenylate cyclase inhibitor SQ22,536. Mol Pharmacol 83: 95-105, 2013.
56. Erdbrügger W, Michel MC, Brodde OE. The β-adrenoceptor antagonist CGP 20712A discriminates between α2-but not α1-adrenoceptor subtypes. Pharmacol Commun 5: 301-305, 1995.
57. Erguven M, Akev N, Ozdemir A, Karabulut E, Bilir A. The inhibitory effect of suramin on telomerase activity and spheroid growth of C6 glioma cells. Med Sci Monit 14: BR165-BR173, 2008.
58. Erickson CE, Gul R, Blessing CP, Nguyen J, Liu T, Pulakat L, Bastepe M, Jackson EK, Andresen BT. The β-blocker nebivolol is a GRK/β-arrestin biased agonist. PLoS One 8: e71980, 2013.
59. Evans BA, Hutchinson DS, Summers RJ.β2-Adrenoceptor-mediated regulation of glucose uptake in skeletal muscle—ligand-directed signalling or a reflection of system complexity? Naunyn Schmiedebergs Arch Pharmacol 386: 757-760, 2013.
60. Evans BA, Sato M, Sarwar M, Hutchinson DS, Summers RJ. Liganddirected signalling at β-adrenoceptors. Br J Pharmacol 159: 1022-1038, 2010.
61. Everaerts W, Sepulveda MR, Gevaert T, Roskams T, Nilius B, de Ridder D. Where is TRPV1 expressed in the bladder, do we see the real channel? Naunyn Schmiedebergs Arch Pharmacol 379: 421-425, 2009.
62. Feldman RD, Park GD, Lai CY. The interaction of verapamil and norverapamil with β-adrenergic receptors. Circulation 72: 547-554, 1985.
63. Ferro A. β-adrenoceptors and potassium channels. Naunyn Schmiedebergs Arch Pharmacol 373: 183-185, 2006.
64. Fossetta J, Deno G, Gonsiorek W, Fan X, Lavey B, Das P, Lunn C, Zavodny PJ, Lundell D, Hipkin RW. Pharmacological characterization of human S1P4 using a novel radioligand, [4,5-3H]-dihydrosphingosine-1-phosphate. Br J Pharmacol 142: 851-860, 2004.
65. Frazier EP, Braverman AS, Peters SL, Michel MC, Ruggieri MR Sr. Does phospholipase C mediate muscarinic receptor-induced rat urinary bladder contraction? J Pharmacol Exp Ther 322: 998-1002, 2007.
66. Frazier EP, Mathy MJ, Peters SL, Michel MC. Does cyclic AMP mediate rat urinary bladder relaxation by isoproterenol? J Pharmacol Exp Ther 313: 260-267, 2005.
67. Frazier EP, Michel-Reher MB, van Loenen P, Sand C, Schneider T, Peters SL, Michel MC. Lack of evidence that nebivolol is a β3-adrenoceptor agonist. Eur J Pharmacol 654: 86-91, 2011.
68. Frazier EP, Peters SL, Braverman AS, Ruggieri MR Sr, Michel MC. Signal transduction underlying control of urinary bladder smooth muscle tone by muscarinic receptors and β-adrenoceptors. Naunyn Schmiedebergs Arch Pharmacol 377: 449-462, 2008.
69. Fredriksson R, Lagerström MC, Lundin LG, Schiöth HB. The Gprotein-coupled receptors in the human genome form five main families. Phylogenetic analysis, paralogon groups, and fingerprints. Mol Pharmacol 63: 1256-1272, 2003.
70. Fredriksson R, Schiöth HB. The repertoire of G-protein-coupled receptors in fully sequenced genomes. Mol Pharmacol 67: 1414-1425, 2005.
71. Freissmuth M, Boehm S, Beindl W, Nickel P, Ijzerman AP, Hohenegger M, Nanoff C. Suramin analogues as subtype-selective G protein inhibitors. Mol Pharmacol 49: 602-611, 1996.
72. Galandrin S, Oligny-Longpré G, Bonin H, Ogawa K, Galés C, Bouvier M. Conformational rearrangements and signaling cascades involved in ligand-biased mitogen-activated protein kinase signaling through the β1-adrenergic receptor. Mol Pharmacol 74: 162-172, 2008.
73. Gesty-Palmer D, Yuan L, Martin B, Wood WH 3rd, Lee MH, Janech MG, Tsoi LC, Zheng J, Luttrell LM, Maudsley S.β-Arrestin-selective G protein-coupled receptor agonists engender unique biological efficacy in vivo. Mol Endocrinol 27: 296-314, 2013.
74. Ghraf R, Michel MC, Hiemke C, Knuppen R. Competition by monophenolic estrogens and catecholestrogens for high-affinity uptake of [3H](-)-norepinephrine into synaptosomes from rat cerebral cortex and hypothalamus. Brain Res 277: 163-168, 1983.
75. Gillman PK. Tricyclic antidepressant pharmacology and therapeutic drug interactions updated. Br J Pharmacol 151: 737-748, 2007.
76. Gutierrez-de-Teran H, Massink A, Rodriguez D, Liu W, Han GW, Joseph JS, Katritch I, Heitman LH, Xia L, Ijzerman AP, Cherezov V, Katritch V, Stevens RC. The role of a sodium ion binding site in the allosteric modulation of the A2A adenosine G protein-coupled receptor. Structure 21: 2175-2185, 2013.
77. Haenisch B, Bönisch H. Interaction of the human plasma membrane monoamine transporter (hPMAT) with antidepressants and antipsychotics. Naunyn Schmiedebergs Arch Pharmacol 381: 33-39, 2010.
78. Haenisch B, Drescher E, Thiermer L, Xin H, Giros B, Gautron S, Bönisch H. Interaction of antidepressant and antipsychotic drugs with the human organic cation transporters hOCT1, hOCT2 and hOCT3. Naunyn Schmiedebergs Arch Pharmacol 385: 1017-1023, 2012.
79. Hagelüken A, Nürnberg B, Harhammer R, Grünbaum L, Schunack W, Seifert R. The class III antiarrhythmic drug amiodarone directly activates pertussis toxin-sensitive G proteins. Mol Pharmacol 47: 234-240, 1995.
80. Han C, Abel PW, Minneman KP. Heterogeneity of α1-adrenergic receptors revealed by chloroethylclonidine. Mol Pharmacol 32: 505-510, 1987.
81. Harmati G, Papp F, Szentandrassy N, Barandi L, Ruzsnavszky F, Horvath B, Banyasz T, Magyar J, Panyi G, Krasznai Z, Nanasi PP. Effects of the PKC inhibitors chelerythrine and bisindolylmaleimide I (GF 109203X) on delayed rectifier K+ currents. Naunyn Schmiedebergs Arch Pharmacol 383: 141-148, 2011.
82. Heger M, van Golen RF, Broekgaarden M, Michel MC. The molecular basis for the pharmacokinetics and pharmacodynamics of curcumin and its metabolites in relation to cancer. Pharmacol Rev 66: 222-307, 2014.
83. Heijman J, Dobrev D. Pleiotropic actions of amiodarone: still puzzling after half a century. Naunyn Schmiedebergs Arch Pharmacol 386: 571-574, 2013.
84. Hein P, Goepel M, Cotecchia S, Michel MC. A quantitative analysis of antagonism and inverse agonism at wild-type and constitutively active hamster α1B-adrenoceptors. Naunyn Schmiedebergs Arch Pharmacol 363: 34-39, 2001.
85. Higashijima T, Uzu S, Nakajima T, Ross EM. Mastoparan, a peptide toxin from wasp venom, mimics receptors by activating GTP-binding regulatory proteins (G proteins). J Biol Chem 263: 6491-6494, 1988.
86. Himmel HM, Glossmann H, Ravens U. Naftopidil, a new β-adrenoceptor blocking agent with calcium antagonistic properties: characterization of Ca2+ antagonistic effects. J Cardiovasc Pharmacol 17: 213-221, 1991.
87. Hoffmann C, Leitz MR, Oberdorf-Maass S, Lohse MJ, Klotz KN. Comparative pharmacology of human β-adrenergic receptor subtypes— characterization of stably transfected receptors in CHO cells. Naunyn Schmiedebergs Arch Pharmacol 369: 151-159, 2004.
88. Hohenegger M, Waldhoer M, Beindl W, Böing B, Kreimeyer A, Nickel P, Nanoff C, Freissmuth M. Gsα-selective G protein antagonists. Proc Natl Acad Sci USA 95: 346-351, 1998.
89. Hollenberg MD, Mihara K, Polley D, Suen JY, Han A, Fairlie DP, Ramachandran R. Biased signalling and proteinase-activated receptors (PARS): targeting inflammatory disease. Br J Pharmacol 171: 1180-1194, 2014.
90. Hoste AM, Sys SU. Ca2+ channel-blocking activity of propranolol and betaxolol in isolated bovine retinal microartery. J Cardiovasc Pharmacol 32: 390-396, 1998.
91. Howard MJ, Hughes RJ, Motulsky HJ, Mullen MD, Insel PA. Interactions of amiloride with α-and β-adrenergic receptors: amiloride reveals an allosteric site on α2-adrenergic receptors. Mol Pharmacol 32: 53-58, 1987.
92. Howard MJ, Mullen MD, Insel PA. Amiloride interacts with renal α-and β-adrenergic receptors. Am J Physiol Renal Fluid Electrolyte Physiol 253: F21-F25, 1987.
93. Howl J, Yarwood NJ, Davies AR, Wheatley M. Renal bradykinin and vasopressin receptors: ligand selectivity and classification. Kidney Int 50: 586-592, 1996.
94. Hrooka K, Kelly ME, Baldridge WH, Bames S. Suppressive actions of betaxolol on ionic currents in retinal ganglion cells may explain its neuroprotective effects. Exp Eye Res 70: 611-621, 2000.
95. Hübner M, Dixit A, Mou TC, Lushington GH, Pinto C, Gille A, Geduhn J, König B, Sprang SR, Seifert R. Structural basis for the high-affinity inhibition of mammalian membranous adenylyl cyclase by 2’,3’-O-(N-methylanthraniloyl)-inosine 5’-trisphosphate. Mol Pharmacol 80: 87-96, 2011.
96. Hübner M, Dizayee S, Matthes J, Seifert R, Herzig S. Effect of MANT-nucleotides on L-type calcium currents in murine cardiomyocytes. Naunyn Schmiedebergs Arch Pharmacol 383: 573-583, 2011.
97. Hughes SA, Gibson WJ, Young JM. The interaction of U-73122 with the histamine H1 receptor: implications for the use of U-73122 in defining H1 receptor-coupled signalling pathways. Naunyn Schmiedebergs Arch Pharmacol 362: 555-558, 2000.
98. Hutchinson DS, Sato M, Evans BA, Christopoulos A, Summers RJ. Evidence for pleiotropic signaling at the mouse β3-adrenoceptor revealed by SR59230A [3-(2-ethylphenoxy)-1-[(1,S)-1,2,3,4-tetrahydronapth-1-ylamino]-2S-2-propanol oxalate]. J Pharmacol Exp Ther 312: 1064-1074, 2005.
99. Iwatsubo K, Minamisawa S, Tsunematsu T, Nakagome M, Toya Y, Tomlinson JE, Umemura S, Scarborough RM, Levy DE, Ishikawa Y. Direct inhibition of type 5 adenylyl cyclase prevents myocardial apoptosis without functional deterioration. J Biol Chem 279: 40938-40945, 2004.
100. Janssen DA, Hoenderop JG, Jansen KC, Kemp AW, Heesakkers JP, Schalken JA. The mechanoreceptor TRPV4 is localized in adherence junctions of the human bladder urothelium: a morphological study. J Urol 186: 1121-1127, 2011.
101. Jenkinson DH, Barnard EA, Hoyer D, Humphrey PP, Leff P, Shankley NP. International Union of Pharmacology Committee on Receptor Nomenclature and Drug Classification. IX. Recommendations on terms and symbols in quantitative pharmacology. Pharmacol Rev 47: 255-266, 1995.
102. Jones S, Howl J. Biological applications of the receptor mimetic peptide mastoparan. Curr Protein Pept Sci 7: 501-508, 2006.
103. Joost HG, Steinfelder HJ. Forskolin inhibits insulin-stimulated glucose transporter in rat adipose cells by a direct interaction with the glucose transporter. Mol Pharmacol 31: 279-283, 1987.
104. Kassack MU, Braun K, Ganso M, Ullmann H, Nickel P, Böing B, Müller G, Lambrecht G. Structure-activity relationships of analogues of NF449 confirm NF449 as the most potent and selective known P2X1 receptor antagonist. Eur J Med Chem 39: 325-357, 2004.
105. Keffel S, Alexandrov A, Goepel M, Michel MC.α1-Adrenoceptor subtypes differentially couple to growth promotion and inhibition in Chinese hamster ovary cells. Biochem Biophys Res Commun 272: 906-911, 2000.
106. Kelly E. Efficacy and ligand bias at the μ-opioid receptor. Br J Pharmacol 169: 1430-1446, 2013.
107. Kenakin T, Christopoulos A. Signalling bias in new drug discovery: detection, quantification and therapeutic impact. Nat Rev Drug Discov 12: 205-216, 2013.
108. Kenakin T, Jenkinson S, Watson C. Determining the potency and molecular mechanism of action of insurmountable antagonists. J Pharmacol Exp Ther 319: 710-723, 2006.
109. Khakh BS, Burnstock G, Kennedy C, King BF, North RA, Sequela P, Voigt M, Humphrey PP. International Union of Pharmacology. XXIV. Current status of the nomenclature and properties of P2X receptors and their subunits. Pharmacol Rev 53: 107-118, 2001.
110. Khan SM, Sleno R, Gora S, Zylbergold P, Laverdure JP, Labbé JC, Miller GJ, Hébert TE. The expanding roles of Gβγ subunits in G protein-coupled receptor signaling and drug action. Pharmacol Rev 65: 545-577, 2013.
111. Kirkpatrick P. Specificity concerns with antibodies for receptor mapping. Nat Rev Drug Discov 8: 278, 2009.
112. Klinker JF, Hagelüken A, Grünbaum L, Heilmann I, Nürnberg B, Harhammer R, Offermanns S, Schwaner I, Ervens J, Wenzel-Seifert K, Müller T, Seifert R. Mastoparan may activate GTP hydrolysis by Gi-proteins in HL-60 membranes indirectly through interaction with nucleoside diphosphate kinase. Biochem J 304: 377-383, 1994.
113. Kories C, Czyborra C, Fetscher C, Schneider T, Krege S, Michel MC. Gender comparison of muscarinic receptor expression and function in rat and human urinary bladder: differential regulation of M2 and M3? Naunyn Schmiedebergs Arch Pharmacol 367: 524-531, 2003.
114. Kruse AC, Ring AM, Manglik A, Hu J, Hu K, Eitel K, Hübner H, Pardon E, Valant C, Sexton PM, Christopoulos A, Felder CC, Gmeiner P, Steyaert J, Weis WI, Garcia KC, Wess J, Kobilka BK. Activation and allosteric modulation of a muscarinic acetylcholine receptor. Nature 504: 101-106, 2013.
115. Kume H, Hall IP, Washabau RJ, Takagi K, Lotlikoff MI.β-Adrenergic agonists regulate KCa channels in airway smooth muscle by cAMPdependent and-independent mechanisms. J Clin Invest 93: 371-379, 1994.
116. Laurila JM, Xhaard H, Ruuskanen JO, Rantanen MJ, Karlsson HK, Johnson MS, Scheinin M. The second extracellular loop of α2A adrenoceptors contributes to the binding of yohimbine analogues. Br J Pharmacol 151: 1293-1304, 2007.
117. Laux WH, Pande P, Shoshani I, Gao J, Boudou-Vivet V, Gosselin G, Johnson RA. Pro-nucleotide inhibitors of adenylyl cyclases in intact cells. J Biol Chem 279: 13317-13332, 2004.
118. Leiros CP, Sterin-Borda L, Borda ES, Goin JC, Hosey MM. Desensitization and sequestration of human m2 muscarinic acetylcholine receptors by autoantibodies from patients with Chagas’ disease. J Biol Chem 272: 12989-12993, 1997.
119. Leppik RA, Birdsall NJ. Agonist binding and function at the human α2A-adrenoceptor: allosteric modulation by amilorides. Mol Pharmacol 58: 1091-1099, 2000.
120. Leppik RA, Lazareno S, Mynett A, Birdsall NJ. Characterization of the allosteric interactions between antagonists and amiloride analogues at the human α2A-adrenergic receptor. Mol Pharmacol 53: 916-925, 1998.
121. Levay M, Krobert KA, Wittig K, Voigt N, Bermudez M, Wolber G, Dobrev D, Levy FO, Wieland T. NSC23766, a widely used inhibitor of Rac1 activation, additionally acts as a competitive antagonist at muscarinic acetylcholine receptors. J Pharmacol Exp Ther 347: 69-79, 2013.
122. Liggett SB. Functional properties of the rat and human β3-adrenergic receptors: differential agonist activation of recombinant receptors in Chinese hamster ovary cells. Mol Pharmacol 42: 634-637, 1992.
123. Link R, Daunt D, Barsh G, Chruscinski A, Kobilka B. Cloning of two mouse genes encoding α2-adrenergic receptor subtypes and identification of a single amino acid in the mouse α2-C10 homolog responsible for an interspecies variation in antagonist binding. Mol Pharmacol 42: 16-27, 1992.
124. Lockhart LK, McNicol A. The phospholipase C inhibitor U73122 inhibits phorbol ester-induced platelet activation. J Pharmacol Exp Ther 289: 721-728, 1999.
125. Macrez-Lepretre N, Morel JL, Mironneau J. Effects of phospholipase C inhibitors on Ca2+ channel stimulation and Ca2+ release from intracellular stores evoked by α1A-and α2A-adrenoceptors in rat portal vein myocytes. Biochem Biophys Res Commun 218: 30-34, 1996.
126. Mastrangelo E, Pezzullo M, Tarantino D, Petazzi R, Germani F, Kramer D, Robel I, Rohayem J, Bolognesi M, Milani M. Structurebased inhibition of Norovirus RNA-dependent RNA polymerases. J Mol Biol 419: 198-210, 2012.
127. McMillan D, McCarron JG. The phospholipase C inhibitor U-73122 inhibits Ca2+ release from the intracellular sarcoplasmic reticulum Ca2+ store by inhibiting Ca2+ pumps in smooth muscle. Br J Pharmacol 160: 1295-1301, 2010.
128. Mehra D, Imtiaz MS, van Helden DF, Knollmann BC, Laver DR. Multiple modes of ryanodine receptor 2 inhibition by flecainide. Mol Pharmacol 86: 696-706, 2014.
129. Melena J, Stanton D, Osborne NN. Comparative effects of antiglaucoma drugs on voltage-dependent calcium channels. Graefes Arch Clin Exp Ophthalmol 239: 522-530, 2001.
130. Melena J, Wood JP, Osborne NN. Betaxolol, a β1-adrenoceptor antagonist, has an affinity for L-type Ca2+ channels. Eur J Pharmacol 378: 317-322, 1999.
131. Michel MC, Bressel HU, Goepel M, Rübben H. A 6-month large-scale study into the safety of tamsulosin. Br J Clin Pharmacol 51: 609-614, 2001.
132. Michel MC, Brodde OE, Schnepel B, Behrendt J, Tschada R, Motulsky HJ, Insel PA. [3H]Idazoxan and some other α2-adrenergic drugs also bind with high affinity to a non-adrenergic site. Mol Pharmacol 35: 324-330, 1989.
133. Michel MC, Foster C, Brunner HR, Liu L. A systematic comparison of the properties of clinically used angiotensin II type 1 receptor antagonists. Pharmacol Rev 65: 809-848, 2013.
134. Michel MC, Insel PA. Making sense out of antisense for the study of drug receptors. J Clin Invest 98: 1074-1075, 1996.
135. Michel MC, Kenny BA, Schwinn DA. Classification of α1-adrenoceptor subtypes. Naunyn Schmiedebergs Arch Pharmacol 352: 1-10, 1995.
136. Michel MC, Kerker J, Branchek TA, Forray C. Selective irreversible binding of chloroethylclonidine at α1-and α2-adrenoceptor subtypes. Mol Pharmacol 44: 1165-1170, 1993.
137. Michel MC, Rother A, Hiemke C, Ghraf R. Inhibition of synaptosomal high-affinity uptake of dopamine and serotonin by estrogen agonists and antagonists. Biochem Pharmacol 36: 3175-3180, 1987.
138. Michel MC, Seifert R, Bond RA. Dynamic bias and its implications for GPCR drug discovery. Nat Rev Drug Discov 13: 869-870, 2014.
139. Michel MC, Wieland T, Tsujimoto G. How reliable are G-proteincoupled receptor antibodies? Naunyn Schmiedebergs Arch Pharmacol 377: 385-388, 2009.
140. Mijares A, Lebesgue D, Wallukat G, Hoebeke J. From agonist to antagonist: Fab fragments of an agonist-like monoclonal anti-β2-adrenoceptor antibody behave as antagonists. Mol Pharmacol 58: 373-379, 2000.
141. Min J, DeFea K. β-Arrestin-dependent actin reorganization: bringing the right players together at the leading edge. Mol Pharmacol 80: 760-768, 2011.
142. Miura S, Okabe A, Matsuo Y, Karnik SS, Saku K. Unique binding behavior of the recently approved angiotensin II receptor blocker azilsartan compared with that of candesartan. Hypertens Res 36: 134-139, 2013.
143. Mogami H, Lloyd Mills C, Gallacher DV. Phospholipase C inhibitor, U73122, releases intracellular Ca2+, potentiates Ins(1,4,5)P3-mediated Ca2+ release and directly activates ion channels in mouse pancreatic acinar cells. Biochem J 324: 645-651, 1997.
144. Monczor F, Fernandez N, Fitzsimons CP, Shayo C, Davio C. Antihistaminergics and inverse agonism: potential therapeutic applications. Eur J Pharmacol 715: 26-32, 2013.
145. Moser N, Mechawar N, Jones I, Gochberg-Sarver A, Orr-Utregger A, Plomann M, Salas R, Molles B, Marubio L, Roth U, Maskos U, Winzer-Serhan U, Bourgeois JP, Le Sourd AM, De Biasi M, Schröder H, Lindstrom J, Maelicke A, Changeux JP, Wevers A. Evaluating the suitability of nicotinic acetylcholine receptor antibodies for standard immunodetection procedures. J Neurochem 102: 479-492, 2007.
146. Motulsky HJ, Snavely MD, Hughes RJ, Insel PA. Interaction of verapamil and other calcium channel blockers with α1-and α2-adrenergic receptors. Circ Res 52: 226-231, 1983.
147. Müller F, Fromm MF. Transporter-mediated drug-drug interactions. Pharmacogenomics 12: 1017-1037, 2011.
148. Musgrave IF, Genieser HG, Maronde E, Seifert R. Preparations of Rp-cyclic adenosine 3’,5’-phosphorothioate (Rp-cAMPS) can contain biologically active amounts of adenosine. FEBS Lett 318: 227-230, 1993.
149. Muto Y, Nagao T, Urushidani T. The putative phospholipase C inhibitor U73122 and its negative control, U73343, elicit unexpected effects on the rabbit parietal cell. J Pharmacol Exp Ther 282: 1379-1388, 1997.
150. Nahmias C, Blin N, Elalouf JM, Mattei MG, Strosberg AD, Emorine LJ. Molecular characterization of the mouse β3-adrenergic receptor: relationship with the atypical receptor of adipocytes. EMBO J 10: 3721-3727, 1991.
151. Nelson CP, Nahorski SR, Chaliss RA. Constitutive activity and inverse agonism at the M2 muscarinic acetylcholine receptor. J Pharmacol Exp Ther 316: 279-288, 2006.
152. Neubig RR, Spedding M, Kenakin T, Christopoulos A. International Union of Pharmacology Committee on Receptor Nomenclature and Drug Classification. XXXVIII. Update on terms and symbols in quantitative pharmacology. Pharmacol Rev 55: 597-606, 2003.
153. Neumann D, Schneider EH. Analysis of histamine receptor knockout mice in models of inflammation. J Pharmacol Exp Ther 348: 2-11, 2014.
154. Ngala RA, O’Dowd JF, Stocker CJ, Cawthorne MA, Arch JR. β2-Adrenoceptor agonists can both stimulate and inhibit glucose uptake in mouse soleus muscle through ligand-directed signalling. Naunyn Schmiedebergs Arch Pharmacol 386: 761-773, 2013.
155. O’Rourke MF, Iversen LJ, Lomasney JW, Bylund DB. Species orthologs of the alpha-2A adrenergic receptor: the pharmacological properties of the bovine and rat receptors differ from human and porcine receptors. J Pharmacol Exp Ther 271: 735-740, 1994.
156. Parnot C, Miserey-Lenkei S, Bardin S, Corvol P, Clauser E. Lessons from constitutively active mutants of G protein-coupled receptors. Trends Endocrinol Metab 13: 336-343, 2002.
157. Polat B, Cadirci E, Halici Z, Bayir Y, Unal D, Bilgin BC, Yuksel TN, Vancelik S. The protective effect of amiodarone in lung tissue of cecal ligation and puncture-induced septic rats: a perspective from inflammatory cytokine release and oxidative stress. Naunyn Schmiedebergs Arch Pharmacol 386: 635-643, 2013.
158. Poulin H, Bruhova I, Timour Q, Theriault O, Beaulieu JM, Frassati D, Chahine M. Fluoxetine blocks Nav1.5 channels via a mechanism similar to that of class 1 antiarrhythmics. Mol Pharmacol 86: 378-389, 2014.
159. Reiter E, Ahn S, Shukla AK, Lefkowitz RJ. Molecular mechanism of β-arrestin-biased agonism at seven-transmembrane receptors. Annu Rev Pharmacol Toxicol 52: 179-197, 2012.
160. Rhodes KJ, Trimmer JS. Antibodies as valuable neuroscience research tools versus reagents of mass distraction. J Neurosci 26: 8017-8020, 2006.
161. Rodriquez-Puertas R, Barreda-Gomez G. Development of new drugs that act through membrane receptors and involve an action on inverse agonism. Recent Pat CNS Drug Discov 1: 207-217, 2006.
162. Rohrbeck A, von Elsner L, Hagemann S, Just I. Binding of Clostridium botulinum C3 exoenzyme to intact cells. Naunyn Schmiedebergs Arch Pharmacol 387: 523-532, 2014.
163. Rosethorne EM, Charlton SJ. Agonist-biased signaling at the histamine H4 receptor: JNJ7777120 recruits β-arrestin without activating G proteins. Mol Pharmacol 79: 749-757, 2011.
164. Salomone S, Yoshimura S, Reuter U, Foley M, Thomas SS, Moskowitz MA, Waeber C. S1P3 receptors mediate the potent constriction of cerebral arteries by sphingosine-1-phosphate. Eur J Pharmacol 469: 125-134, 2003.
165. Sand C, Michel MC. Bradykinin contracts rat urinary bladder largely independent of phospholipase C. J Pharmacol Exp Ther 348: 25-31, 2014.
166. Sanni SJ, Hansen JT, Bonde MM, Speerschneider T, Christensen GL, Munk S, Gammeltoft S, Hansen JL. β-Arrestin 1 and 2 stabilize the angiotensin II type 1 receptor in distinct high-affinity conformations. Br J Pharmacol 161: 150-161, 2010.
167. Sato M, Horinouchi T, Hutchinson DS, Evans BA, Summers RJ. Ligand-directed signaling at the β3-adrenoceptor produced by SR59230A relative to receptor agonists. Mol Pharmacol 74: 1359-1368, 2007.
168. Schmidt M, Dekker FJ, Maarsingh H. Exchange protein directly activated by cAMP (epac): a multidomain cAMP mediator in the regulation of diverse biological functions. Pharmacol Rev 65: 670-709, 2013.
169. Schmidt RH, Jokinen JD, Massey VL, Falkner KC, Shi X, Yin X, Zhang X, Beier JI, Arteel GE. Olanzapine activates hepatic mammalian target of rapamycin: new mechanistic insight into metabolic dysregulation with atypical antipsychotic drugs. J Pharmacol Exp Ther 347: 126-135, 2013.
170. Schneider EH, Neumann D, Seifert R. Modulation of behavior by the histaminergic system: lessons from H1R-and H2R-deficient mice. Neurosci Biobehav Rev 42: 252-266, 2014.
171. Schneider EH, Neumann D, Seifert R. Modulation of behavior by the histaminergic system: lessons from HDC-, H3R-and H4R-deficient mice. Neurosci Biobehav Rev 47: 101-121, 2014.
172. Schneider T, Fetscher C, Krege S, Michel MC. Signal transduction underlying carbachol-induced contraction of human urinary bladder. J Pharmacol Exp Ther 309: 1148-1153, 2004.
173. Schneider T, Hein P, Michel MC. Signal transduction underlying carbachol-induced contraction of rat urinary bladder. I. Phospholipases and Ca2+ sources. J Pharmacol Exp Ther 308: 47-53, 2004.
174. Schwede F, Maronde E, Geniesser HG, Jastorff B. Cyclic nucleotide analogs as biochemical tools and prospective drugs. Pharmacol Ther 87: 199-226, 2000.
175. Seifert R. Functional selectivity of G-protein-coupled receptors: from recombinant systems to native human cells. Biochem Pharmacol 86: 853-861, 2013.
176. Seifert R. Vidarabine is neither a potent nor a selective AC5 inhibitor. Biochem Pharmacol 84: 543-546, 2014.
177. Seifert R, Lushington GH, Mou TC, Gille A, Sprang SR. Inhibitors of membranous adenylyl cyclases. Trends Pharmacol Sci 33: 64-78, 2012.
178. Seifert R, Schneider EH, Dove S, Brunskole I, Neumann D, Strasser A, Buschauer A. Paradoxical stimulatory effects of the “standard” histamine H4-receptor antagonist JNJ7777120: the H4 joins the club of 7 transmembrane domain receptors exhibiting functional selectivity. Mol Pharmacol 79: 631-638, 2014.
179. Seifert R, Strasser A, Schneider EH, Neumann D, Dove S, Buschauer A. Molecular and cellular analysis of human histamine receptor subtypes. Trends Pharmacol Sci 34: 33-58, 2013.
180. Seifert R, Wenzel-Seifert K. Constitutive activity of G-protein-coupled receptors: cause of disease and common property of wild-type receptors. Naunyn Schmiedebergs Arch Pharmacol 366: 381-416, 2002.
181. Setoguchi M, Ohya Y, Abe I, Fujishima M. Inhibitory action of betaxolol, a β1-selective adrenoceptor antagonist, on voltage-dependent calcium channels in guinea-pig artery and vein. Br J Pharmacol 115: 198-202, 1995.
182. Smit MJ, Vink C, Verzijl D, Casarosa P, Bruggeman CA, Leurs R. Virally encoded G protein-coupled receptors: targets for potentially innovative anti-viral drug development. Curr Drug Targets 4: 431-441, 2003.
183. Smit MJ, Vischer HF, Bakker RA, Jongejan A, Timmerman H, Pardo L, Leurs R. Pharmacogenomic and structural analysis of constitutive G protein-coupled receptor activity. Annu Rev Pharmacol Toxicol 47: 53-87, 2007.
184. Soeder KJ, Snedder SK, Cao W, della Rocca GJ, Daniel KW, Luttrell LM, Collins S. The β3-adrenergic receptor activates mitogenactivated protein kinase in adipocytes through a Gi-dependent mechanism. J Biol Chem 274: 12017-12022, 1999.
185. Sprossmann F, Pankert P, Sausbier U, Wirth A, Zhou XB, Madlung J, Zhao H, Bucrenciu I, Jakob A, Lamkemeyer T, Neuhuber W, Offermanns S, Shipston MJ, Korth M, Nordheim A, Ruth P, Sausbier M. Inducible knockout mutagenesis reveals compensatory mechanisms elicited by constitutive BK channel deficiency in overactive murine bladder. FEBS J 276: 1680-1697, 2009.
186. Stallaert W, Dorn JF, van der Westhuizen E, Audet M, Bouvier M. Impedance responses reveal β2-adrenergic receptor signaling pluridimensionality and allow classification of ligands with distinct signaling profiles. PLoS One 7: e29420, 2012.
187. Strasser A, Wittmann HJ, Buschauer A, Schneider EH, Seifert R. Species-dependent activities of G-protein-coupled receptor ligands: lessons from histamine receptor orthologs. Trends Pharmacol Sci 34: 13-32, 2013.
188. Strasser A, Wittmann HJ, Schneider EH, Seifert R. Modulation of GPCRs by monovalent cations and anions. Naunyn Schmiedebergs Arch Pharmacol (November 30, 2014). doi:10.1007/s00210-014-1073-2.
189. Swaminath G, Deupi X, Lee TW, Zhu W, Thian FS, Kobilka TS, Kobilka B. Probing the β2 adrenoceptor binding site with catechol reveals differences in binding and activation by agonists and partial agonists. J Biol Chem 280: 22165-22171, 2005.
190. Talmont F, Mouledous L. Evaluation of commercial antibodies against human sphingosine-1-phosphate receptor 1. Naunyn Schmiedebergs Arch Pharmacol 387: 427-431, 2014.
191. Tanaka Y, Yamashita Y, Yamaki F, Horinouchi T, Shigenobu K, Koike K. Evidence for a significant role of a Gs-triggered mechanism unrelated to the activation of adenylyl cyclase in the cyclic AMPindependent relaxant response of guinea-pig tracheal smooth muscle. Naunyn Schmiedebergs Arch Pharmacol 368: 437-441, 2003.
192. Taniguchi T, Inagaki R, Murata S, Akiba I, Muramatsu I. Microphysiometric analysis of human α1a-adrenoceptor expressed in Chinese hamster ovary cells. Br J Pharmacol 127: 962-968, 1999.
193. Uchida H, Shishido K, Nomiya M, Yamaguchi O. Involvement of cyclic AMP-dependent and-independent mechanisms in the relaxation of rat detrusor muscle via β-adrenoceptors. Eur J Pharmacol 518: 195-202, 2005.
194. van Loenen PB, de Graaf C, Verzijl D, Leurs R, Rognan D, Peters SL, Alewijnse AE. Agonist-dependent effects of mutations in the sphingosine-1-phosphate type 1 receptor. Eur J Pharmacol 667: 105-112, 2011.
195. van Wieringen JP, Michel-Reher MB, Hatanaka T, Ueshima K, Michel MC. The new radioligand [3H]-L 748,337 differentially labels human and rat β3-adrenoceptors. Eur J Pharmacol 720: 124-130, 2013.
196. Vrydag W, Michel MC. Tools to study β3-adrenoceptors. Naunyn Schmiedebergs Arch Pharmacol 374: 385-398, 2007.
197. Wang JP. U-73122, an aminosteroid phospholipase C inhibitor, may also block Ca2+ influx through phospholipase C-independent mechanism in neutrophil activation. Naunyn Schmiedebergs Arch Pharmacol 353: 599-605, 1996.
198. Wenzel K, Haase H, Wallukat G, Derer W, Bartel S, Homuth V, Herse F, Hubner N, Schulz H, Janczikowski M, Lindschau C, Schroeder C, Verlohren S, Morano I, Muller DN, Luft FC, Dietz R, Dechend R, Karczewski P. Potential relevance of α1-adrenergic receptor autoantibodies in refractory hypertension. PLoS One 3: e3742, 2008.
199. Wenzel-Seifert K, Seifert R. Cyclosporin H is a potent and selective formyl peptide receptor antagonist. Comparison with N-t-butoxycarbonyl-L-phenylalanyl-L-leucyl-L-phenylalanyl-L-leucyl-L-phenylalanine and cyclosporins A, B, C, D, and E. J Immunol 150: 4591-4599, 1993.
200. Wenzel-Seifert K, Seifert R. Molecular analysis of β2-adrenoceptor coupling to Gs-, Gi-, and Gq-proteins. Mol Pharmacol 58: 954-966, 2000.
201. Wisler JW, DeWire SM, Whalen EJ, Violin JD, Drake MT, Ahn S, Shenov SK, Lefkowitz RJ. A unique mechanism of β-blocker action: carvedilol stimulates β-arrestin. Proc Natl Acad Sci USA 104: 16657-16662, 2007.
202. Wolner I, Kassack MU, Ullmann H, Karel A, Hohenegger M. Usedependent inhibition of the skeletal muscle ryanodine receptor by the suramin analogue NF676. Br J Pharmacol 146: 525-533, 2005.
203. Wood JP, Schmidt KG, Melena J, Chidlow G, Allmeier H, Osborne NN. The β-adrenoceptor antagonists metipranolol and timolol are retinal neuroprotectants: comparison with betaxolol. Exp Eye Res 76: 505-516, 2003.
204. Wuest M, Hecht J, Christ T, Braeter M, Schoeberl C, Hakenberg OW, Wirth MP, Ravens U. Pharmacodynamics of propiverine and three of its metabolites on detrusor contraction. Br J Pharmacol 145: 608-619, 2005.
205. Wuest M, Weiss A, Waelbrock M, Braeter M, Kelly LU, Hakenberg OW, Ravens U. Propiverine and metabolites: differences in binding to muscarinic receptors and in functional models of detrusor contraction. Naunyn Schmiedebergs Arch Pharmacol 374: 87-97, 2006.
206. Wuest M, Witte LP, Michel-Reher MB, Propping S, Braeter M, Strugala GJ, Wirth MP, Michel MC, Ravens U. The muscarinic receptor antagonist propiverine exhibits α1-adrenoceptor antagonism in human prostate and porcine trigonum. World J Urol 29: 149-155, 2011.
207. Ye RD, Boulay F, Wang JM, Dahlgren C, Gerard C, Parmentier M, Serhan CN, Murphy PM. International Union of Basic and Clinical Pharmacology. LXXIII. Nomenclature for the formyl peptide receptor (FPR) family. Pharmacol Rev 61: 119-161, 2009.
208. Yu W, Hill WG. Lack of specificity shown by P2Y6 receptor antibodies. Naunyn Schmiedebergs Arch Pharmacol 386: 885-891, 2013.